Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma

被引:33
|
作者
Liu, Han [1 ]
Sun, Bo [2 ]
Wang, Shengnan [1 ]
Liu, Congjin [1 ]
Lu, Yun [1 ]
Li, Ding [1 ]
Liu, Xingdang [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Nucl Med, Shanghai, Peoples R China
[2] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai, Peoples R China
关键词
Circulating tumor cells; Pancreatic cancer; Aneuploidy; Biomarker; CANCER PATIENTS; CARCINOMA; SURVIVAL; POLYPLOIDIZATION; IMPROVEMENT; ANEUPLOIDY; DIAGNOSIS; PREDICT; GENOME; BODY;
D O I
10.1159/000477481
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
application for cancer management. In the current study, we evaluated the diagnostic value of CTCs in pancreatic ductal adenocarcinoma (PDAC). Methods: In total, 143 blood samples from 95 consecutively diagnosed PDAC patients and 48 healthy donors were collected. Combined data from immunostaining of CD45, DAPI and fluorescence in situ hybridization (FISH) with chromosome 8 centromere (CEP8) probe were used to identify CTCs. Cells with features of CD45-/DAPI+/CEP8>2 were detected as CTCs. Results: CTCs were classified as triploid, tetraploid and multiploid based on chromosome 8 copy number. CTC subtype composition was significantly different among groups. Both subtype number and total CTC number were significantly increased in PDAC patients, compared to healthy controls. Total CTC number had 75.8% sensitivity and 68.7% specificity at a cutoff value of 2 cells/3.2 mL. This study is the first to report that CTC subtype number is also useful in cancer diagnosis. Sensitivity was 53.7% and specificity was 85.4% at a cutoff point of 2 CTC subtypes. The diagnostic value of both total CTC number and CTC subtype number was a little poorer than CA199. Conclusions: Both CTC subtype and total CTC number may serve as potential biomarkers for PDAC. (C) 2017 The Author(Published by S. Karger AG, Basel
引用
收藏
页码:373 / 382
页数:10
相关论文
共 50 条
  • [11] Can Circulating Tumor Cells be Used to Diagnose Pancreatic Ductal Adenocarcinoma in Surgical Candidates?
    Perkins, J.
    Pitman, M.
    Fernandez-del Castillo, C.
    Warshaw, A. L.
    Lillemoe, K.
    Liss, A. S.
    Thayer, S. P.
    PANCREAS, 2013, 42 (08) : 1376 - 1376
  • [12] Circulating Monocytes Serve as Novel Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma Patients
    Hansen, Frederik J.
    David, Paul
    Akram, Marina
    Knoedler, Samuel
    Mittelstaedt, Anke
    Merkel, Susanne
    Podolska, Malgorzata J.
    Swierzy, Izabela
    Rossdeutsch, Lotta
    Kloesch, Bettina
    Kouhestani, Dina
    Anthuber, Anna
    Benard, Alan
    Brunner, Maximilian
    Krautz, Christian
    Gruetzmann, Robert
    Weber, Georg F.
    CANCERS, 2023, 15 (02)
  • [13] Biomarker detection in pancreatic ductal adenocarcinoma
    Klett, H.
    Klose, M.
    Kowar, S.
    Bronsert, P.
    Kuesters, S.
    Werner, M.
    Christoph, P.
    Busch, H.
    Boerries, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S177 - S178
  • [14] Protein biomarker for pancreatic ductal adenocarcinoma
    Burki, Talha K.
    LANCET ONCOLOGY, 2017, 18 (09): : E511 - E511
  • [15] Identifying and Correlating Circulating Tumor Cells and Cell- Free DNA in Pancreatic Ductal Adenocarcinoma
    Baugh, K.
    Cagigas, M. Navarro
    Fisher, W.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S147 - S147
  • [16] Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
    Song, Byeong Geun
    Kwon, Wooil
    Kim, Hyemin
    Lee, Eun Mi
    Han, Young Min
    Kim, Hongbeom
    Byun, Yoonhyeong
    Lee, Kyung Bun
    Lee, Kwang Hyuck
    Lee, Kyu Taek
    Lee, Jong Kyun
    Jang, Jin-Young
    Park, Joo Kyung
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [17] Prognostic significance of circulating tumor microemboli in patients with pancreatic ductal adenocarcinoma
    Wu, Guangdong
    Zhu, Rongrong
    Li, Yatong
    Zhao, Yupei
    Dai, Menghua
    ONCOLOGY LETTERS, 2018, 15 (05) : 7376 - 7382
  • [18] ALCAM as a Novel Circulating Tumor Cell Marker for Pancreatic Ductal Adenocarcinoma
    Jacob, H. K. C.
    Signorelli, R.
    Richard, J. L. C.
    Giret, T. M.
    Kashuv, T.
    Gomez, B. A.
    Middleton, A.
    Lavania, S.
    Dudeja, V.
    Saluja, A. K.
    PANCREAS, 2020, 49 (10) : 1413 - 1413
  • [19] Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival
    Amantini, Consuelo
    Morelli, Maria Beatrice
    Nabissi, Massimo
    Piva, Francesco
    Marinelli, Oliviero
    Maggio, Federica
    Bianchi, Francesca
    Bittoni, Alessandro
    Berardi, Rossana
    Giampieri, Riccardo
    Santoni, Giorgio
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [20] Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma
    Guan, Shasha
    Deng, Guochao
    Sun, Jingjie
    Han, Quanli
    Lv, Yao
    Xue, Tianhui
    Ding, Lijuan
    Yang, Tongxin
    Qian, Niansong
    Dai, Guanghai
    FRONTIERS IN ONCOLOGY, 2022, 12